Combination cytokine therapy: The next generation of rheumatoid arthritis therapy?

Arthritis Care and Research

Volumn 47, Issue 1, 2002, Pages 87-92

  Kavanaugh, Arthur ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; B7 ANTIGEN INHIBITOR; CD28 ANTIGEN INHIBITOR; CD29 ANTIGEN INHIBITOR; CD40 ANTIGEN INHIBITOR; CD40 LIGAND MONOCLONAL ANTIBODY; CD86 ANTIGEN INHIBITOR; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12 INHIBITOR; INTERLEUKIN 2 INHIBITOR; INTERLEUKIN 4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1 INHIBITOR; OKT 4; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1 INHIBITOR;

ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 0036169758     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art1.10158     Document Type: Article

References (27)

1. Infliximab and methotrexate in the treatment of rheumatoid arthritis
2. Anticytokine therapy: A new era in the treatment of rheumatoid arthritis?
3. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
4. Inhibitors of tumor necrosis factor (TNF) in rheumatoid arthritis: Will that dog hunt?
5. Updating a reassessment of traditional paradigms concerning rheumatoid arthritis
6. Does partial control of inflammation prevent long-term joint damage? Clinical rationale for combination therapy with multiple disease-modifying anti-rheumatic drugs
7. Cytokines in rheumatoid arthritis
8. Role of cytokines in rheumatoid arthritis
9. Intraarticular variability of synovial membrane histology, immunohistology, and cytokine mRNA expression in patients with rheumatoid arthritis
10. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: Evidence for synergistic interactions between cytokines in vivo
11. Therapeutic actions of cyclosporine and anti-tumor necrosis factor a in collagen-induced arthritis and the effect of combination therapy
12. The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies
13. The pathogen connection
14. IL-1α/β blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation
15. Anti-interleukin-1 and anti-tumor necrosis factor-α synergistically inhibit adjuvant arthritis in Lewis rats
16. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PE-Gylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis
17. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
18. Interleukin 10 treatment for rheumatoid arthritis
19. Viral IL-10 and soluble TNF receptor act synergistically to inhibit collagen-induced arthritis following adenovirus-mediated gene transfer
20. Synergisitc activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis
21. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen induced arthritis
22. A comparative study into the mechanisms of action of anti-tumor necrosis factor α, anti-CD4, and combined anti-tumor necrosis factor α/anti-CD4 treatment in early collagen-induced arthritis
23. Access to disease modifying treatments for rheumatoid arthritis patients
24. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis
25. Cutting edge: Combined treatment of TNF-α and IFN-γ causes redistribution of junctional adhesion molecule in human endothelial cells
26. Interaction between tumor necrosis factor microsatellite polymorphisms and the HLA-DRB1 shared epitope in rheumatoid arthritis: Influence on disease outcome
27. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNFα binding to its receptor